Pricing
How much does Zepbound cost without insurance in 2026?
Zepbound vial and KwikPen cash prices, the $449 Journey refill condition, regular fallback prices and how to estimate total spending.
Claims are checked against the sources cited in this article. Nothing here is individualized medical advice. How we research
On this page
As checked October 9, 2026, Lilly lists a 28-day Zepbound self-pay supply—four vials or one KwikPen—at $299 for 2.5 mg, $399 for 5 mg, and $449 for qualifying higher-strength purchases. The $449 offer has a refill-purchase condition; without it, the regular price is $499 for 7.5 mg or $699 for 10, 12.5 or 15 mg, before required pen needles or vial needles and syringes, and any other added charges. LillyDirect and Lilly’s purchase terms are the primary sources.
LillyDirect requires those supply purchases but does not show their prices on the product page, so the medication table is not a complete final bill. It describes the single-dose vials as self-pay only with free delivery.
Zepbound cash prices by strength and package
The table labels products for price comparison, not strengths to select or a treatment schedule.
| Strength | Qualifying self-pay purchase price | Regular price when the Journey offer does not apply |
|---|---|---|
| 2.5 mg | $299 | $299 |
| 5 mg | $399 | $399 |
| 7.5 mg | $449 | $499 |
| 10 mg | $449 | $699 |
| 12.5 mg | $449 | $699 |
| 15 mg | $449 | $699 |
These prices describe a 28-day supply containing four single-dose vials or one single-patient-use KwikPen. They do not describe the separate single-dose pen offer. The LillyDirect price reference distinguishes these presentations.
The condition behind the $449 Journey price
The Journey offer applies to the first purchase at 7.5, 10, 12.5 or 15 mg. Continued eligibility requires completing the refill purchase within 45 days of the previous delivery or receipt. Additional taxes and fees may apply, and Lilly may change the offer. These are the manufacturer’s purchase conditions.
That is a purchasing rule, not a medical instruction. Do not change a prescription or refill timing for an advertised discount; ask the care team and pharmacy how the actual prescription and applicable offer fit together. If the pharmacy quotes a different amount, first check which form, strength and purchase program it used.
For budgeting, the fallback price matters. The difference between $449 and $499 is $50 per package; between $449 and $699 it is $250. Those amounts help explain why a quote should state whether it includes the Journey offer. They do not establish eligibility or predict whether an individual purchase will qualify.
Ask the pharmacy to show the offer applied on the receipt. A website starting price is not the same as a confirmed checkout charge, and an expected discount should remain conditional until the purchase is processed.
Why the form belongs beside every Zepbound price
A price comparison that says only “Zepbound” can mix vial, KwikPen and single-dose pen offers. Put the complete form name in your worksheet, alongside the strength and package quantity. This makes two quotes comparable without requiring you to interpret the manufacturer’s different program names from memory.
The same principle applies when a telehealth platform advertises access to a manufacturer pharmacy. Access does not establish the platform’s own fee, and it does not mean every Zepbound presentation has the same price. Request the exact pharmacy quote for the prescription rather than treating a platform’s marketing range as a final bill.
Our tirzepatide guide explains the provider-directory context. Its links and our weight-care listings can help identify services to investigate, but they are not confirmations of pharmacy inventory or an individual prescription decision.
A transparent first-12-week estimate
Three 28-day packages cover 84 days, or 12 weeks. If all three actual packages qualify at $449, the medication subtotal is $1,347. At $499 each, it is $1,497; at $699 each, it is $2,097. Add the required pen needles or vial needles and syringes: LillyDirect does not list their prices on the product page, so those unquoted purchases are not included in the subtotals. These are fixed-price illustrations, not a recommendation to start or remain at any particular strength.
The first-period total should include every mandatory payment needed to obtain those supplies. Add any separately confirmed consultation, membership, laboratory, shipping, supply or tax charges. If a provider requires a longer prepaid commitment, show the full cash payment due as well as the amount attributable to the comparison period.
Do not construct a supposedly universal 12-week total by choosing a sequence of strengths yourself. Obtain the price of the actual prescribed packages. If the plan or quoted package changes, revise the worksheet rather than leaving an outdated introductory calculation in place.
Keep ongoing spending in a second column. A program can have an attractive first purchase but a different recurring service fee, and a medication discount can have conditions that do not apply to the platform subscription. Showing both columns makes the financial commitments visible.
Does the $25 card replace these cash prices?
Lilly’s commercial-insurance offer for covered single-dose pens is separate from its vial and KwikPen self-pay programs. The covered pen card lists monthly savings caps and an annual $1,300 maximum across up to 13 fills. The commercial savings page explains that program; it is not a universal uninsured price.
The separate KwikPen self-pay card permits up to 11 fills and expires December 31, 2026. Its cash transactions do not count toward insurance deductibles or out-of-pocket requirements. Those card terms are distinct from the Journey purchase terms, so do not infer that every vial offer has the card’s expiration date.
An insured reader should ask for a confirmed plan-processed quote and, where relevant, a separately labeled cash quote. Compare the amounts actually payable under each route. Do not stack discounts merely because both appear on a manufacturer website.
Comparing with compounded tirzepatide
Compounded tirzepatide prices should remain in their own category. FDA states that compounded medicines are not FDA-approved and do not receive its premarket review; a matching ingredient name is not a basis for treating an offer as a branded Zepbound quote. FDA’s compounding explanation describes the regulatory distinction.
Our compounded tirzepatide comparison separates required payments and commitments for reviewed offers. Use it to examine billing, not to infer interchangeability. For Zepbound itself, the clearest budget names the form, records the refill-offer condition, includes mandatory service charges and shows the fallback price beside the discounted one.
In that October 6 compounded comparison, Gentle Health’s starting tier and Mochi Health’s representative starting-dose example both total $169 monthly; Mochi’s example includes its standard $79 membership. It is a tie between those stated examples, not a universal cheapest-provider finding. Gentle’s terms require two monthly payments; Mochi’s account-specific price and possible charges still need confirmation. Higher tiers and commitments change the budget, and none of these figures describes branded Zepbound.